Skip to content

How Asthra compares

Honest comparisons against generic LLMs, dedicated regulatory AI platforms, and manual authoring — so you can decide where Asthra fits and where it doesn't.

Every team evaluating AI for regulatory writing already has three alternatives on the table: a general-purpose LLM like ChatGPT or Claude used directly; a dedicated regulatory-AI platform; or the status quo — manual authoring by experienced regulatory writers. Below, Asthra is compared to each on the capabilities that actually drive a buy decision in regulated life sciences.

Asthra vs. generic LLMs (ChatGPT, Claude direct, etc.)

What changes when the LLM is wrapped in a regulated-writing system

CapabilityAsthra AIGeneric LLMs
Closed-system retrieval (no open-internet, no training-memory leakage)
Retrieval is locked to your uploaded source documents only.
General-purpose LLMs retrieve from training memory and often the open web.
Sentence-level citations with file, page, and exact passage
On-demand for every generated claim.
Some general chat UIs can attempt citations, but they are generated post-hoc and routinely incorrect.
Flags missing or contradictory source data
Gaps surface inline; no fabrication.
Generic LLMs fill gaps with plausible invention.
Works natively inside Microsoft Word
Word add-in with task pane, track changes, and in-document refinement.
Copy-paste workflow between a chat UI and Word.
Template-specific, section-by-section drafting
Onboarded per template (ICH E3, ICH E2C, EU MDR, eCTD Module 3).
Prompt-by-prompt generation; template fidelity relies on the user.
Immutable transaction ledger embedded in the .docx
Audit trail travels with the document.
Chat history is ephemeral and not embedded in the output.
No customer data used for model training
Contractual via Anthropic commercial API + Asthra terms.
Depends on the plan and settings; often requires enterprise tier.
SOC 2 / ISO 27001 / HIPAA / GDPR posture
SOC 2 Type 1 ready; SOC 2 Type 2, ISO 27001, GDPR, HIPAA in progress.
Varies by vendor and plan; rarely life-sciences-specific.

Takeaway. Generic LLMs are excellent general writers. They lose in regulated environments on the three things that matter most — closed-system retrieval, honest citations, and an audit trail that travels with the document.

Asthra vs. dedicated regulatory AI platforms

Among purpose-built platforms, where Asthra is different

CapabilityAsthra AIOther regulatory AI platforms
Writer-defined provenance (human sets source rules per section)
Configured during template onboarding, enforced at retrieval time.
Some platforms rely on the model to choose sources, with human review after.
Agentic drafting loop with human-approvable retrieval plan
Plan → Retrieve → Draft → Hand off. Writer can approve the plan before drafting runs.
Many platforms run end-to-end generation without an approval checkpoint.
Chat-mode refinement after the draft
Natural-language edits inside Word, using the same closed-system retrieval.
Usually a separate prompt cycle; citations may not update automatically.
Built on Anthropic Claude
Claude Opus / Sonnet / Haiku selected per task.
Many use GPT-family models; model choice is often opaque.
Support across CSR, PSUR / PBRER / DSUR, CER, and CMC Module 3
All four are production document types today.
Most platforms specialise in one or two of these and partner for the rest.
Managed SaaS or customer-managed VPC deployment
AWS, Azure, or GCP VPC for customers with data-residency or validation requirements.
Not all platforms offer VPC deployment.

Takeaway. Most purpose-built platforms got the document-type coverage right. Asthra's differentiators are the human-approvable retrieval plan, chat-mode refinement inside Word, and the .docx-embedded transaction ledger — all aimed at making the audit trail travel with the writer, not stay in a vendor's backend.

Asthra vs. manual authoring

Where writer time gets reclaimed — and where it still belongs

CapabilityAsthra AIManual authoring
Time to CSR first draft
About 30 minutes of agent time; writer review on top.
Typically 6+ weeks per study.
Time to PSUR first draft
About 60 minutes of agent time; writer review on top.
Weeks of synthesis across fragmented safety sources.
Consistency across sections and reporting periods
Session-level caching + template-level prompts keep the voice and structure stable.
Depends on writer continuity and QC rigor.
Sentence-level traceability without extra effort
Generated during drafting, not retrofitted.
Possible manually, but expensive and easy to drop under deadline pressure.
Full clinical and regulatory judgment
Asthra drafts; writers interpret, conclude, and sign off.
Qualified humans retain full judgment authority.
Complex statistical reanalysis
Out of scope — Asthra reports from the sources, it does not recompute.
Statisticians and programmers handle this upstream.

Takeaway. Asthra collapses the mechanical half of authoring (retrieval, reformatting, initial narrative, cross-referencing). The interpretive half — clinical judgment, benefit-risk, sign-off — stays with the writer, which is where it belongs.

Where Asthra is not the right fit

Asthra is not a statistical analysis tool. It reports what the source documents contain and does not recompute TFL, re-derive populations, or run primary statistics. That work belongs upstream with your biostatistics team.

Asthra is not a clinical judgment system. Benefit-risk conclusions, causality assessments, and regulatory strategy remain with qualified medical and regulatory professionals. Asthra surfaces evidence; humans decide what it means.

Asthra is not a document management system. It reads from your DMS when you integrate one, but it does not replace one. Version control, access policy, and long-term archive belong in your DMS of record.

If your use case is outside regulated life-sciences writing — general business documents, marketing copy, code — Asthra is the wrong tool. Use a general-purpose LLM for those.

See Asthra next to what you're using today

Request a demo. Bring the document type you care about. We'll show you exactly where Asthra changes the picture — and where it doesn't.

Request a demo

Last updated: 16 April 2026